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Metaplastic breast carcinoma is very rare, and metaplastic
carcinoma with chondroid differentiation is even rarer. Here,
we report a case of metaplastic carcinoma with extensive
chondroid differentiation mimicking chondrosarcoma that was
challenging to diagnose. The tumor was characterized by an
abundant chondromyxoid matrix. The definitive area of classic
invasive ductal carcinoma was minimal. The peripheral portion
of the tumor showed increased cellularity with pleomorphism
and definitive invasive growth. Tumor cells in the chondrosar-
comatous areas were diffusely immunoreactive for S-100 pro-
tein, patchy positive for cytokeratin, but negative for epithelial
membrane antigen (EMA). Tumor cells in carcinomatous areas
were diffusely positive for cytokeratin, S-100 protein, and
patchy positive for EMA. In both areas, tumor cells were nega-
tive for smooth muscle actin (SMA) and CD34, while oncopro-
tein p53 was overexpressed. When pathologists encounter
breast tumors with chondroid differentiation, careful sampling
and immunohistochemistry for cytokeratin and SMA are most
helpful to differentiate metaplastic carcinoma from malignant
phyllodes tumor and malignant adenomyoepithelioma.
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INTRODUCTION
In the human breast, the incidence of cartilagin-
ous lesion is very rare. In less than 5% of breast
carcinomas, part or all of the carcinomatous epi-
thelium is transformed into a mesenchymal histo-
logical pattern by metaplastic processes.1
Metaplastic carcinomas (MCs) are highly hetero-
geneous groups of tumors that are characterized
by an admixture of adenocarcinoma with domi-
nant areas of spindle cell, squamous, and/or
mesenchymal differentiation.1,2 Heterologous mesen-
chymal elements range from areas of bland to
frank sarcoma such as chondrosarcoma (CS),
osteosarcoma, rhabdomyosarcoma, liposarcoma or
fibrosarcoma, among which cartilaginous and
osseous metaplasia are the most commonly en-
countered.3
We report a case of MC with extensive chon-
droid differentiation (so-called chondroid carci-
noma), mimicking CS. Differentiating diagnoses
was difficult, and possible diagnoses included
malignant phyllodes tumor (PT), malignant adeno-
myoepithelial tumor with chondroid matrix, and
MC with CS.
MCs require treatment as invasive ductal carci-
nomas, thus axillary lymph node dissection must
be considered. As a result, differential diagnosis
for MC is essential and can be achieved by careful
sampling and immunohistochemistry for panels of
epithelial markers such as cytokeratin and EMA,
and myoepithelial markers such as S-100 protein
and SMA.3-5
CASE REPORT
A 59-year-old woman developed a breast lump
in the right upper central area. She had received
hormone replacement therapy for 1 year. Ultra-
sonogram revealed a 2.3 × 0.9 cm irregularly mar-
ginated mass with posterior enhancement. How-
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ever, Doppler ultrasonography demonstrated no
increase in blood flow. Mammography showed an
asymmetric parenchymal lesion, which appeared
to be a malignant tumor. A partial mastectomy
was performed, based on the diagnosis of malig-
nant PT, using ultrasonography-guided core
needle biopsy. The specimen obtained by partial
mastectomy measured 17 × 13 × 2 cm. The cut sur-
face showed a 3.3 × 1.3 cm mass with a lobulated
margin. The cut surface of the tumor was
whitish-gray, solid, and devoid of necrosis.
On histological examination, the tumor had a
strikingly abundant chondromyxoid matrix with
variable cellularity. The tumor cells were relatively
small, monomorphous and round. However, a
mild degree of anisocytosis was identified and
mitotic figures were frequent, with an average of
5 mitotic figures per 10 high power fields. The
tumor had an invasive lobulated margin. Tumor
cells were more cellular in the peripheral margin
of the nodules and had perinuclear clear spaces,
suggesting a malignant tumor with chondrosar-
comatous features.
Although definitive carcinomatous areas were
minimal, tumor cells in those areas were diffusely
positive for cytokeratin and S-100 protein, and
were patchy positive for EMA (Fig. 1). In chondro-
sarcomatous areas, tumor cells were diffusely im-
munoreactive for S-100 protein and patchy posi-
tive for cytokeratin (Fig. 2), but were negative for
EMA. In both chondrosarcomatous and carcino-
matous areas, tumor cells stained negatively for
both smooth muscle actin (SMA) and CD34 (Fig.
3). Estrogen and progesterone receptors were
absent. Tumor cells were found to overexpress the
p53 oncoprotein, but not the HER-2/neu oncopro-
tein. The tumor was diagnosed as MC with chond-
roid differentiation, a so-called chondroid carci-
noma.
Postoperatively, the patient received 6 cycles of
chemotherapy with actinomycin-D and cyclopho-
sphamide. In addition, external radiation therapy
(5940 cGy) was performed. The patient was doing
well at the 5-month postoperative follow-up,
without evidence of tumor recurrence or metas-
tasis.
DISCUSSION
Cartilaginous lesions are very rare in the breast.
Benign tumors, specifically chondrolipoma and
pleomorphic adenoma, may contain benign chond-
roid tissue, but the presence of malignant chond-
roid tissue is indeed rare.
In the primary breast tumor, chondrosarcomat-
ous lesions may occur in three different forms: a
pure CS, as a heterologous component of a
malignant PT or as a chondrosarcomatous dif-
ferentiation in a MC.4 In less than 5% of breast
carcinomas, part or all of the carcinomatous epi-
thelium is transformed into a nonglandular
mesenchymal tissue by metaplastic processes.1
A case of malignant PT with chondrosarcomat-
ous overgrowth was reported in which the chon-
drosarcomatous component constituted over 80%
of the tumor volume.4 If not well sampled for the
areas of characteristic leaf-like pattern or benign
Fig. 1. The tumor cells grow in highly infiltrative pattern. In that carcinomatous area (A), the tumor cells are diffusely
positive for cytokeratin (B).
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ductal epithelium, the malignant PT may be mis-
diagnosed as pure CS, especially in the case of a
tumor with extensive chondrosarcomatous over-
growth. Therefore, complete and meticulous tu-
mor sampling is very important as demonstrated
by the present case. Even though PTs are biphasic
tumors, cytokeratin is not expressed in the stro-
mal element. Moreover, CD34 and bcl-2 are more
frequently expressed in PTs than in MCs.3 The
tumor in our present case was negative for CD34
and had no characteristic features suggesting PT,
such as cleft-like spaces or benign ductal elements.
Immunohistochemistry for panels of epithelial
markers, such as cytokeratin and EMA, can help
differentiate malignant PT from MC with hetero-
logous chondrosarcomatous elements.3,4
MCs are highly heterogeneous groups of tu-
mors and can be classified into broad subtypes
according to the phenotypic appearance of the
tumor: purely epithelial or mixed epithelial and
mesenchymal. MCs are characterized by an ad-
mixture of adenocarcinoma with dominant areas
of spindle cell, squamous, and/or mesenchymal
differentiation.
1,2
Heterologous mesenchymal ele-
ments range from areas of bland chondroid and
osseous differentiation to frank sarcoma such as
chondrosarcoma, osteosarcoma, rhabdomyosar-
coma, liposarcoma or fibrosarcoma, among which
cartilaginous and osseous metaplasia are the most
commonly encountered.3 MC with sarcomatoid
areas are much rarer than those with benign meta-
plasia. MCs predominantly composed of meta-
plastic elements with a minor component of inva-
sive adenocarcinoma have been designated by
varied terminology, including carcinosarcoma,
sarcomatoid carcinoma, spindle cell carcinoma,
Fig. 2. The tumor shows extensive chondroid matrix with perinuclear halo (A). In that chondrosarcomatous area, the tumor
cells are patchy-positive for cytokeratin (B).
Fig. 3. Immunostaining shows diffuse positive reactivity with S-100 protein (A), but negativity with smooth muscle actin
(B).
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carcinoma with pseudosarcomatous metaplasia,
and a spindle cell variant of MC. These diverse
appellations can lead to confusion when dia-
gnosed. Currently the favored explanation for the
origin of the mesenchymal component of these
tumors is a metaplastic change originating from
epithelial or myoepithelial elements.2 Even though
the frequency of metaplasia, including both homo-
logous and heterologous tissues in the breast,
tends to be underreported, heterologous meta-
plasia is reported to occur in 0.2% of breast car-
cinomas.6
Myoepithelial neoplasms of the breast are ex-
tremely rare and have been thought to behave as
low-grade malignant tumors with the potential to
recur locally and, very rarely, to metastasize. The
characteristics of malignant myoepithelioma
(myoepithelial carcinoma) overlap with those of
MCs in that both tumors express S-100 protein
and cytokeratins.3 SMA may be positive in epi-
thelial areas in 25% of MCs, which indicates that
MCs show strong immunohistochemical evidence
of myoepithelial differentiation, in addition to
expressing basal-specific cytokeratins.3,7
In summary, immunohistochemistry for epi-
thelial markers, such as cytokeratin and EMA, is
important to rule out pure sarcoma or PTs. Im-
munohistochemistry for SMA is useful to dis-
tinguish MC with chondroid differentiation from
myoepithelial carcinoma with a chondroid matrix.
Popnikolov et al. reported that increased EMA
expression in carcinomas with chondroid matrix
contrasts with decreased EMA expression in MCs
with spindle cells, which tend instead to show
higher expression of SMA.5 Because MCs often
appear to originate from poorly differentiated
ductal carcinoma, they are usually negative for
estrogen and progesterone receptors.1,8 Even
though overexpression of p53 supports a diag-
nosis of MC, it is only observed in fewer than 50%
of the cases. In spindle cell type and matrix-pro-
ducing type MCs, the frequency of HER-2/neu
overexpression is variable, ranging from negative
to 33%.5,9,10 This suggests that HER-2/neu may not
be helpful in differentiating those entities. The
tumor in our present case was negative for hor-
monal receptors and HER-2/neu, but overex-
pressed p53 and had a high proliferation index.
Because MCs are so rare, and long-term follow-
up data in large series of cases are scarce, it has
been difficult to predict the clinical behavior of
these tumors. MCs with osteocartilaginous
heterologous elements were reported to have a
better prognosis, because axillary lymph node
metastases are less frequent than in nonmeta-
plastic invasive ductal carcinoma.10 Large collec-
tive case studies are needed to explore the clinical
and physiological behavior of these tumors and to
clarify the therapeutic options. MCs require treat-
ment, as would the usual mammary carcinoma.
According to the tumor stage, axillary lymph
node dissection should be considered. Unfortu-
nately, lymph node dissection was not undertaken
in this case because it was originally misdiagno-
sed as malignant PT with chondrosarcomatous
elements. However, the patient has been doing
well after post-operative chemotherapy and radia-
tion therapy.
In conclusion, when a pathologist encounters a
malignant breast tumor with chondroid elements,
MC with chondroid differentiation should be con-
sidered, even though an epithelial component
may be minimal or absent. Thorough sampling
and immunohistochemistry for cytokeratin and
SMA are essential to confirm the diagnosis.
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